OTC: PHMMF - Pharma Mar, S.A.

Rentabilité sur six mois: +7.88%
Rendement en dividendes: 2.09%
Secteur: Healthcare

Calendrier des promotions Pharma Mar, S.A.

Calendrier avancé Graphique simple
Financial Markets by TradingView

À propos de l'entreprise Pharma Mar, S.A.

Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles of marine origin for use in oncology in Spain, Italy, Germany, Ireland, France, rest of EU, the United States, and internationally. The company operates through Oncology and RNA interference segments. It develops and commercializes Yondelis for the treatment of soft tissue sarcoma and for ovarian cancer; Aplidin for treating R/R multiple myeloma; and Zepzelca for treating patients with small cell lung cancer.

plus de détails
The company also develops PM14, which is in phase II clinical trials for the treatment of solid tumors, as well as in Phase I clinical trial for the treatment of soft tissue sarcoma and prostate cancer; PM534 that is Phase I clinical trial for treating solid tumors; Tivanisiran, which is in Phase III clinical trial for the treatment of dry eye disease; and SYL1801 that is in phase II clinical trial for treating macular degeneration. In addition, it engages in the development, production, and sale of products with therapeutic activity based on reducing or silencing gene expression. The company was incorporated in 1986 and is based in Madrid, Spain.
Ajouter à la liste de comparaison
Ajouter à la liste de surveillance
Ajouter au portefeuille
Ajouter un avis de prix

ISIN ES0169501022
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Див.доход ао 2.09
Дивиденд ао 0.6266
Сайт https://www.pharmamar.com
Цена ао 80.91
Changement de prix par jour: 0% (80.91)
Changement de prix par semaine: -8.25% (88.183)
Changement de prix par mois: -8.25% (88.183)
Changement de prix sur 3 mois: -15.53% (95.79)
Changement de prix sur six mois: +7.88% (75)
Changement de prix par an: +159.74% (31.15)
Evolution du prix sur 3 ans: -0.8456% (81.6)
Evolution du prix sur 5 ans: +4 988.68% (1.59)
Evolution des prix depuis le début de l'année: -0.1974% (81.07)
Tous les paramètres

Sous-estimation

Nom Signification Grade
P/S 7.86 1
P/BV 6.6 1
P/E 52.63 2
EV/EBITDA 64.21 1
Total: 2.25

Efficacité

Nom Signification Grade
ROA, % 7.94 2
ROE, % 13.63 4
Total: 2.67

Dividendes

Nom Signification Grade
Div yield, % 2.09 5.23
DSI 0.9286 9.29
Total: 4.83

Devoir

Nom Signification Grade
Debt/EBITDA 2.41 6
Total: 8.4

Impulsion de croissance

Nom Signification Grade
Rentabilité Revenue, % -19.4 0
Rentabilité Ebitda, % -83.13 0
Rentabilité EPS, % -75.26 0
Total: 0
Plus de détails

Plus de détails

Établissements Volume Partager, %
Legato Capital Management LLC 3481 0.02



Superviseur Titre d'emploi Paiement Année de naissance
Mr. Jose Maria Fernandez Sousa-Faro Ph.D. Founder, Executive Chairman, CEO & President 320.14k
Mr. Pedro Francisco Fernandez Puentes Executive Vice-Chairman 135.03k
Mr. Juan Carlos-Torres Carretero Founder N/A 1949 (76 années)
Ms. María Luisa de Francia Caballero Chief Financial Officer N/A
Mr. José Luis Moreno Martinez-Losa Head of Capital Markets & Investor Relations N/A
Mr. Juan Gomez Pulido General Counsel & Secretary of the Board of Directors N/A
Ms. Sandra Llamera Sanchez Global Compliance Head N/A
Ms. Lara Vadillo Communication Director N/A
Ms. Belén Sopesén Veramendi Ph.D. Director of Corporate Development N/A
Mr. Luis Rupérez Cuenca Director of Human Resources & IT N/A

Adresse: Spain, Madrid, Avenida de los Reyes. 1 - ouvrir dans Google Maps, ouvrir les cartes Yandex
Site web: https://www.pharmamar.com